| Literature DB >> 29514898 |
Diana-Alexandra Ertl1, Andreas Gleiss2, Katharina Schubert1, Caroline Culen1, Peer Hauck3, Johannes Ott4, Alois Gessl5, Gabriele Haeusler6.
Abstract
BACKGROUND: Previous studies have shown that only a minority of patients with Turner syndrome (TS) have adequate medical care after transfer to adult care. AIM OF THIS STUDY: To assess the status of medical follow-up and quality of life (QoL) in adult women diagnosed with TS and followed up until transfer. To compare the subjective and objective view of the medical care quality and initiate improvements based on patients' experiences and current recommendations.Entities:
Keywords: Turner syndrome; comorbidities; follow-up; health care; health status; quality of life
Year: 2018 PMID: 29514898 PMCID: PMC5881433 DOI: 10.1530/EC-18-0053
Source DB: PubMed Journal: Endocr Connect ISSN: 2049-3614 Impact factor: 3.335
Figure 1Recruitment and study process.
Study population: demographics.
| Median (min–max) | |
|---|---|
| Age at diagnosis (years) | 10.6 (0.1–17.5) |
| Age at GH-therapy (years) | 9.9 (3.9–16.5) |
| Duration of GH-therapy (months) | 48.5 (7–143) |
| Final height (SDS*) | −3.5 ((−6.5) to (−0.94)) |
| BMI** at transfer | 21.5 (14.1–33.8) |
| Time spent in adult follow-up (years) | 17 (3–25) |
| Age at study recruitment | 35 (21–43) |
*Standard deviation score; **body mass index.
Body mass index distribution in the study group and in the Austrian general population.
| BMI study population ( | BMI Austrian population* (%) | |||||
|---|---|---|---|---|---|---|
| Age groups | <25 | 25–30 | >30 | <25 | 25–30 | >30 |
| 15–30 years | 6/12 (50) | 2/12 (17) | 4/12 (33) | 63.6 | 12.8 | 5.7 |
| 30–45 years | 10/27 (37) | 9/27 (33) | 8/27 (30) | 65 | 21.1 | 9.1 |
*Statistik Austria 2014/2015.
Diagnosed comorbidities – summary for the 39 participants.
| Diagnosis | At the time of transition ( | After transition ( | During the study ( |
|---|---|---|---|
| Cardiovascular system | |||
| Aortic coarctation and other abnormalities requiring surgery | 6 | – | – |
| Bicuspid aortic valve | 3 | – | 3 |
| Other abnormalities of aortic valves | 3 | – | – |
| Abnormalities of the aorta | – | 1 | 3 |
| Mitral valve prolapse/insufficiency | – | – | 2 |
| Hypertension | 4 | 3 | 4 |
| Urinary tract | |||
| Congenital malformations | 14 | – | – |
| Acquired pathologies | – | 2 | – |
| Endocrine system | |||
| Hypothyroidism | – | 9 | 3 |
| Thyroid cancer | – | 2 | – |
| Class III obesity | – | – | 3 |
| Type I diabetes | – | 1 | – |
| Type II diabetes | – | – | 1 |
| Gastrointestinal system | |||
| Celiac disease | 1 | – | 1 |
| Crohn’s disease | – | – | |
| Steatosis | – | 2 | – |
| Hepatic dysfunction | – | 2 | 21 |
| Depression | – | 3 | 2 |
Estrogen and current medical care status: subjective vs objective estimation.
| Adequate ( | Inadequate ( | |
|---|---|---|
| Estrogen status | ||
| Subjective | 27/39 | 12/39 |
| Objective | 21/39 | 18/39 |
| Actual medical care | ||
| Subjective | 25/39 | 14/39 |
| Objective | 3/39 | 36/39 |
Figure 2QoL scoring in percentages ‘at the general population norm’ (within 45 and 55, i.e. mean ± ½ s.d. of the SF-36V2 reference population), ‘above the general population’ (above 55, i.e. above mean + ½ s.d.) and ‘below the general population’ (below 45, i.e. below mean − ½ s.d.).
Figure 3Boxplots showing QoL data distribution for all the 8 sections of the domains analyzed. PCS, physical component summary; MCS, mental component summary; PF, physical functioning; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotional; MH, mental health. Horizontal lines refer to mean (50) and mean ± ½ s.d. (45 and 55, respectively) of the SF-36V2 reference population.